Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 3:12:175.
doi: 10.1186/1471-2334-12-175.

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

David R Strutton  1 , Raymond A Farkouh, Jaime L Rubin, Lisa J McGarry, Paul M Loiacono, Keith P Klugman, Steven I Pelton, Kristen E Gilmore, Milton C Weinstein
Affiliations

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

David R Strutton et al. BMC Infect Dis. .

Abstract

Background: Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.

Methods: This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.

Results: Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤ 59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.

Conclusions: Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

PubMed Disclaimer

References

    1. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59:258–261. - PubMed
    1. Nuorti JP, Whitney CG. Centers for Disease Control and Prevention (CDC) Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2010;59:1–18. - PubMed
    1. Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28:7634–7643. doi: 10.1016/j.vaccine.2010.09.049. - DOI - PubMed
    1. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months — selected U.S. regions, 2010–2011. Morbid Mortal Wkly Rep. 2011;60:1477–1481. - PubMed
    1. Health Advisory: Fatal vaccine-preventable pneumococcal disease. http://www.cdph.ca.gov/programs/immunize/Documents/HealthAdvisoryPneumoc....

Publication types

Substances